RT-114

Unknown / undisclosed

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Company guidance: data expected in 2027 (RANI Therapeutics, 9 Nov 2026). “The Phase 1b study will assess the safety, tolerability, and pharmacodynamic effect of eight weeks of repeat dosing with RT-114 in patients with obesity, with data anticipated in 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT06891287 · RANI Therapeutics
2025-12-30 – 2027-06-01 · Obesity
What this study did

Competitive landscape

Other GLP-1/GLP-2 receptor (dual) drugs

dapiglutide, PG-102. Compare all 3 GLP-1/GLP-2 receptor (dual) drugs

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RT-114: this drugPhase 1—GLP-1/GLP-2 receptor (dual)not yet gradedNo reviewed efficacy summary
Dapiglutide
Phase 2(overall)
PeptideGLP-1/GLP-2 receptor (dual)Partial signal
NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed
PG-102
Phase 2(overall)
Protein / enzyme therapeuticGLP-1/GLP-2 receptor (dual)Partial signalFeatured results are safety only

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow RT-114 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1ObesityRecruiting
Est. primary completion 2026-12-01 · NCT06891287 · CT.gov ↗
What to watch

See the full readout calendar ↗